Horizons: a series of opinion & insight articles on disruptive healthcare in practice
Discussing new treatments and how they are set to disrupt healthcare practices in the coming years, the Horizons series aims to kickstart conversation amongst healthcare professionals.
Our first piece is on antibody-drug conjugates (ADCs) and the challenges, practical applications and future potential of this class of drugs. Over the coming weeks, we’ll be tackling topics such as immuno-oncology, oral proteasome inhibitors, CDK 4&6, biosimilars – both as a class and specifics, PARP inhibitors and CAR-T.
Healthcare professionals can get involved by reacting in the comments section.
Read the first piece, Antibody-drug conjugates: elegant concept but impractical application written by Dr Marshall Pearce.